CardioNet's MCOT service: 300,000th patient benefits

CardioNetFeb 4 2010

CardioNet, Inc. (NASDAQ: BEAT) announced today that the 300,000^th patient has been monitored with the Company’s Mobile Cardiac Outpatient Telemetry (MCOT™) service. MCOT is the first system to provide real-time wireless ECG monitoring and 24/7/365 analysis and response.

“The ability to immediately detect a cardiac arrhythmia and then closely monitor the patient for repeat occurrences provides numerous treatment advantages, not the least of which is giving the cardiologist an opportunity to address the condition before it causes a more severe, potentially irreparable outcome”

Randy Thurman, CardioNet Chairman, President and CEO, commented, “With 300,000 patients having now benefited from our MCOT service, it is evident that an increasing number of physicians view real-time, 24/7 monitoring of cardiac arrhythmias as crucial to identifying and preventing life-threatening cardiac-related events such as stroke. The continued availability and adoption of MCOT also brings value to the entire healthcare continuum as it enables physicians to manage arrhythmias before they manifest into more severe conditions that demand significantly greater costs and resources to treat.”

MCOT offers several advantages to physicians, payors, and patients, including: real-time, continuous ECG data analysis; customizable concise reporting to enhance diagnosis and treatment decisions; increased patient compliance through technology and reduced interaction; reflection of real-life cardiac activity; detection of arrhythmias where symptoms are not experienced; minimization of data artifacts or “noise”; two-way wireless capabilities for transmission; ability to associate symptoms and activity with ECG event; remote programming and data retrieval; and the ability to tailor the system to physicians’ needs. Due to these advantages, CardioNet’s MCOT continues to increase its significant leadership position in the mobile cardiac telemetry market.

Dr. Paul Schweitzer, Director of Cardiac Arrhythmia Service at Beth Israel Medical Center and Asst. Chief of Cardiology at Albert Einstein College of Medicine in New York City treated the 300,000th MCOT patient.

“The ability to immediately detect a cardiac arrhythmia and then closely monitor the patient for repeat occurrences provides numerous treatment advantages, not the least of which is giving the cardiologist an opportunity to address the condition before it causes a more severe, potentially irreparable outcome,” said Dr. Schweitzer. “Through its beat-by-beat wireless monitoring, MCOT provides assurance that these sometimes difficult to detect irregularities will be diagnosed in a manner that allows the physician to understand the root cause and prescribe a course of action for the patient’s individual needs.”